Comparing GelStat (OTCMKTS:GSAC) and scPharmaceuticals (NASDAQ:SCPH)

GelStat (OTCMKTS:GSAC) and scPharmaceuticals (NASDAQ:SCPH) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations and earnings.

Volatility & Risk

GelStat has a beta of 2.63, indicating that its share price is 163% more volatile than the S&P 500. Comparatively, scPharmaceuticals has a beta of 0.11, indicating that its share price is 89% less volatile than the S&P 500.

Valuation and Earnings

This table compares GelStat and scPharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GelStat	N/A	N/A	N/A	N/A	N/A
scPharmaceuticals	$30.28 million	5.44	-$54.81 million	($1.90)	-1.73

GelStat has higher earnings, but lower revenue than scPharmaceuticals.

Profitability

This table compares GelStat and scPharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
GelStat	N/A	N/A	N/A
scPharmaceuticals	-264.60%	-244.93%	-68.56%

Insider & Institutional Ownership

89.5% of scPharmaceuticals shares are owned by institutional investors. 20.5% of GelStat shares are owned by insiders. Comparatively, 5.5% of scPharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for GelStat and scPharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GelStat	0	0	0	0	0.00
scPharmaceuticals	0	0	2	0	3.00

scPharmaceuticals has a consensus target price of $15.00, indicating a potential upside of 355.93%. Given scPharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe scPharmaceuticals is more favorable than GelStat.

About GelStat

GelStat Corporation, a consumer health care company, engages in the research, development, and marketing of over-the-counter and other non-prescription consumer health care products. Its products include GelStat Migraine, a patented solution used for pain relief from migraine headaches; Chews 2 Lose, an appetite suppressant gum for diet aide; All Natural Speed, an energy supplement product; and GelStat Sleep, a product for relief from sleep disorders and its associated symptoms. The company sells its products to retailers, wholesalers, specialty distributors, and catalog merchandisers both directly and through external sales brokers. GelStat Corporation was founded in 2002 and is headquartered in Palm City, Florida.

About scPharmaceuticals

scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.